A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma
The researchers are doing this study to find out whether the study vaccines, IO102/IO103, given in combination with the standard-of-care drug combination, nivolumab and relatlimab, is a safe and effective treatment for people with untreated, unresectable melanoma.
Melanoma
DRUG: IO102/IO103|DRUG: Nivolumab-Relatlimab
Overall Response Rate (ORR), will be reported as the proportion of patients who experience a complete (CR) or partial response (PR) to treatment by RECIST v1.1, 3 years
Incidence of adverse events, graded and recorded according to CTCAE v5.0, up to 100 days after the last dose|Progression-free survival (PFS), by RECIST v1.1, 3 years
The researchers are doing this study to find out whether the study vaccines, IO102/IO103, given in combination with the standard-of-care drug combination, nivolumab and relatlimab, is a safe and effective treatment for people with untreated, unresectable melanoma.